Findings from the use of InflaMix, a predictive, point-of-care-clinical tool, designed "to identify patients at high risk of treatment failure and support informed risk-benefit discussions.." in patients with non-Hodgkin lymphoma, were recently published in Nature Medicine. InflaMix, which requires only 1 blood test, "offers an unbiased quantitative assessment of 14 blood markers, 11 of which are routinely assayed for patients with lymphoma."
To read more about InflaMix, click here.
Source mentioned:
Raj SS, Fei T, Fried S, et al. An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nature Medicine; Published online 1 April 2025. DOI: https://doi.org/10.1038/s41591-025-03532-x
No comments:
Post a Comment